|Poll|January 6, 2015

Mini-quiz: Depression and Early Life Trauma

Do persons with depression and a history of early life trauma benefit more from psychotherapy or pharmacotherapy? Take the quiz and learn more.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Phase 3 Program Investigating COMP360 Psilocybin for Treatment-Resistant Depression: Breaking Poster Data From the 2026 ASCP Annual Meeting

ByLeah Kuntz,Guy Goodwin, MD

May 28th 2026

Phase 2b/3 Trial Evaluates Forvisirvat in Major Depressive Disorder

ByJoel Raskin, MD, FRCPC

May 28th 2026

Transdiagnostic Anhedonia: A Conversation With Roger S. McIntyre, MD, FRCPC

ByJohn J. Miller, MD,Roger S. McIntyre, MD, FRCPC

May 27th 2026

Buproprion vs SSRIs: Antidepressant-Naive, Obese Patients With Major Depressive Disorder

ByFarah Khorassani, PharmD

May 27th 2026

The Significant Presence of Comorbidities in Bipolar Depression: Insights From Mark Zimmerman, MD

ByMark Zimmerman, MD

May 27th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Mini-quiz: Depression and Early Life Trauma

Related Content

Phase 3 Program Investigating COMP360 Psilocybin for Treatment-Resistant Depression: Breaking Poster Data From the 2026 ASCP Annual Meeting

Phase 2b/3 Trial Evaluates Forvisirvat in Major Depressive Disorder

Transdiagnostic Anhedonia: A Conversation With Roger S. McIntyre, MD, FRCPC

Buproprion vs SSRIs: Antidepressant-Naive, Obese Patients With Major Depressive Disorder

The Significant Presence of Comorbidities in Bipolar Depression: Insights From Mark Zimmerman, MD

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

Endangered Education: Psychiatric Professional Degrees Under Attack

New Name, New Path for Psychiatry: The Future of the DSM

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability